×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
COLL – collegium pharmaceutical, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
COLL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/10
07:17 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/8
06:07 pm
coll
Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
12/6
02:21 pm
coll
Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]
Low
Report
Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]
11/25
01:49 pm
coll
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at Weiss Ratings.
11/25
07:31 am
coll
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
11/20
05:43 am
coll
Collegium (COLL) Raises 2025 Revenue Guidance—Is Profitability Momentum Built to Last? [Yahoo! Finance]
Low
Report
Collegium (COLL) Raises 2025 Revenue Guidance—Is Profitability Momentum Built to Last? [Yahoo! Finance]
11/19
01:17 pm
coll
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at Weiss Ratings.
11/12
08:48 am
coll
Collegium to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Collegium to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
07:30 am
coll
collegium pharmaceutical, inc.
BEAT
Report
1.1%
collegium pharmaceutical, inc.
8/7/2025
07:30 am
coll
collegium pharmaceutical, inc.
BEAT
Report
9.8%
collegium pharmaceutical, inc.
5/8/2025
04:01 pm
coll
collegium pharmaceutical, inc.
BEAT
Report
5.9%
collegium pharmaceutical, inc.
2/27/2025
04:01 pm
coll
collegium pharmaceutical, inc.
BEAT
Report
2.2%
collegium pharmaceutical, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/10
04:33 pm
coll
Form 4 COLLEGIUM PHARMACEUTICAL For: Dec 08 Filed by: Dreyer Scott
Low
Report
Form 4 COLLEGIUM PHARMACEUTICAL For: Dec 08 Filed by: Dreyer Scott
12/9
04:23 pm
coll
Form 4 COLLEGIUM PHARMACEUTICAL For: Dec 05 Filed by: Balice-Gordon Rita J.
Medium
Report
Form 4 COLLEGIUM PHARMACEUTICAL For: Dec 05 Filed by: Balice-Gordon Rita J.
12/8
04:12 pm
coll
Form 144 COLLEGIUM PHARMACEUTICAL Filed by: Dreyer Scott
Low
Report
Form 144 COLLEGIUM PHARMACEUTICAL Filed by: Dreyer Scott
11/14
04:16 pm
coll
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 12 Filed by: Karnani Vikram
Low
Report
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 12 Filed by: Karnani Vikram
11/14
04:13 pm
coll
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 12 Filed by: Fallon John A.
Low
Report
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 12 Filed by: Fallon John A.
11/13
02:27 pm
coll
Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: RENAISSANCE TECHNOLOGIES LLC
Low
Report
Form SCHEDULE 13G COLLEGIUM PHARMACEUTICAL Filed by: RENAISSANCE TECHNOLOGIES LLC
11/12
04:30 pm
coll
Form 144 COLLEGIUM PHARMACEUTICAL Filed by: Fallon John A.
Low
Report
Form 144 COLLEGIUM PHARMACEUTICAL Filed by: Fallon John A.
11/7
04:23 pm
coll
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 06 Filed by: Tupper Colleen
Low
Report
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 06 Filed by: Tupper Colleen
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/6
Collegium Reports Third Quarter 2019 Financial Results
31.4%
2/6 Collegium to Acquire U.S. Rights to Nucynta Franchise 25.4%
3/13 Collegium Pharmaceutical Inc (NASDAQ: COLL) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 15.8%
11/8 Collegium to Participate in Upcoming Investor Conference 13.9%
1/7 Collegium Provides 2020 Financial Guidance 11.0%
2/27 Q4/2019 12/31/2019 EPS -0.070 ZacksConsensus -0.170 ActVsEst 0.100 - Beat 9.5%
4/3 Form 4 COLLEGIUM PHARMACEUTICAL For: Apr 01 Filed by: Malamut Richard 8.9%
2/11 Form 424B5 COLLEGIUM PHARMACEUTICAL 8.8%
8/7 Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 07 7.4%
3/18 Form 4 COLLEGIUM PHARMACEUTICAL For: Mar 16 Filed by: Kuhlmann Shirley R. 5.7%
2/6 Collegium to Acquire U.S. Rights to Nucynta Franchise 25.4%
3/13 Collegium Pharmaceutical Inc (NASDAQ: COLL) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 15.8%
11/8 Collegium to Participate in Upcoming Investor Conference 13.9%
1/7 Collegium Provides 2020 Financial Guidance 11.0%
2/27 Q4/2019 12/31/2019 EPS -0.070 ZacksConsensus -0.170 ActVsEst 0.100 - Beat 9.5%
4/3 Form 4 COLLEGIUM PHARMACEUTICAL For: Apr 01 Filed by: Malamut Richard 8.9%
2/11 Form 424B5 COLLEGIUM PHARMACEUTICAL 8.8%
8/7 Form 8-K COLLEGIUM PHARMACEUTICAL For: Aug 07 7.4%
3/18 Form 4 COLLEGIUM PHARMACEUTICAL For: Mar 16 Filed by: Kuhlmann Shirley R. 5.7%
TOP News Decliners
2/7
Form 4 COLLEGIUM PHARMACEUTICAL For: Feb 05 Filed by: Malamut Richard
-15.7%
12/2 Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 29 Filed by: Ciaffoni Joseph -6.0%
12/30 Collegium Pharmaceutical Inc (NASDAQ: COLL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock. -5.3%
11/8 Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 07 Filed by: Ciaffoni Joseph -4.9%
5/17 Form 4 COLLEGIUM PHARMACEUTICAL For: May 15 Filed by: Heffernan Michael Thomas -4.3%
8/13 Form 4 COLLEGIUM PHARMACEUTICAL For: Aug 09 Filed by: Fleming Alison B -4.3%
2/13 Collegium Announces Closing of the Nucynta Franchise Acquisition -3.7%
7/16 Collegium Pharmaceutical Inc (NASDAQ: COLL) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -3.6%
3/31 Form EFFECT COLLEGIUM PHARMACEUTICAL -3.5%
7/17 Form 4 COLLEGIUM PHARMACEUTICAL For: Jul 15 Filed by: Heffernan Michael Thomas -3.3%
12/2 Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 29 Filed by: Ciaffoni Joseph -6.0%
12/30 Collegium Pharmaceutical Inc (NASDAQ: COLL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock. -5.3%
11/8 Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 07 Filed by: Ciaffoni Joseph -4.9%
5/17 Form 4 COLLEGIUM PHARMACEUTICAL For: May 15 Filed by: Heffernan Michael Thomas -4.3%
8/13 Form 4 COLLEGIUM PHARMACEUTICAL For: Aug 09 Filed by: Fleming Alison B -4.3%
2/13 Collegium Announces Closing of the Nucynta Franchise Acquisition -3.7%
7/16 Collegium Pharmaceutical Inc (NASDAQ: COLL) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -3.6%
3/31 Form EFFECT COLLEGIUM PHARMACEUTICAL -3.5%
7/17 Form 4 COLLEGIUM PHARMACEUTICAL For: Jul 15 Filed by: Heffernan Michael Thomas -3.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: